1. Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials
- Author
-
Alisa J. Stephens-Shields, Shehzad Basaria, Peter Preston, Thomas W. Storer, Jane A. Cauley, David Cella, Susan S. Ellenberg, Thomas M. Gill, Kristine E. Ensrud, Marco Pahor, John T. Farrar, Peter J. Snyder, and Shalender Bhasin
- Subjects
Male ,medicine.medical_specialty ,Population ,Minimal Clinically Important Difference ,Much Worse ,Walk Test ,Disease ,030204 cardiovascular system & hematology ,Article ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Physical medicine and rehabilitation ,Randomized controlled trial ,law ,medicine ,Humans ,Testosterone ,Patient Reported Outcome Measures ,030212 general & internal medicine ,Mobility Limitation ,Baseline (configuration management) ,education ,Aged ,education.field_of_study ,business.industry ,Testosterone (patch) ,Physical Functional Performance ,Regression ,Walking Speed ,Treatment Outcome ,Dimensional Measurement Accuracy ,Androgens ,Independent Living ,Geriatrics and Gerontology ,business - Abstract
BACKGROUND: Accurate estimates of clinically important difference (CID) are required for interpreting the clinical importance of treatments to improve physical function, but CID estimates vary in different disease populations. AIMS: We determined the CID of 6-minute walking distance (6MWD) and physical function component (PF10) of Medical Outcomes Study Short Form-36 in mobility-limited older men using the Testosterone Trials (TTrials) data. METHODS: TTrials participants (n=429) with mobility limitation and gait speed
- Published
- 2020